Abstract
Current ovarian cancer treatments based on surgery/chemotherapy show limited efficacy. Targeting immunosuppression is a requirement for the effectiveness of novel promising anti-tumor immunotherapies. Our latest work in preclinical models shows that nanoparticle-mediated delivery of immunostimulatory microRNAs specifically to tumor-associated leukocytes is sufficient to re-program immunological control of metastatic ovarian cancers.